Topical treatment for DME tolerated in first-in-human trial

HONOLULU — Safety and tolerability objectives were met in a phase 1/2 first-in-human study of topical SF0166, a topical ophthalmic solution candidate for treatment of diabetic macular edema, a speaker said here.
“Safety and tolerability were excellent, and there was no evidence of corneal toxicity,” D. Scott Edwards, PhD, said at the Association for Research in Vision and Ophthalmology meeting.
Edwards presented data from a randomized, double-masked, multicenter study of 40 patients with DME randomized 1:1 in two arms to receive 1.25 mg or 2.5 mg SF0166 (SciFluor) twice a day

Full Story →